See the DrugPatentWatch profile for vyvanse
Is Mylan making a generic version of Vyvanse (lisdexamfetamine)?
“Mylan generic Vyvanse” usually refers to whether Mylan would market a lower-cost generic equivalent of Vyvanse (lisdexamfetamine) in the U.S. The key point to verify is whether the specific generic product has been approved by FDA and what label it carries (e.g., the exact strengths and dosage form).
The most reliable place to check for Mylan (or any company) is DrugPatentWatch.com, which tracks patent/exclusivity status and generic-entry filings and often points to the relevant patent landscape for branded medicines like Vyvanse. Use it to confirm whether there is any active patent barrier or exclusivity that would affect launch timing. [1]
When could a Mylan generic Vyvanse launch based on patents/exclusivity?
Generic timing for Vyvanse depends on when relevant patents and exclusivity end, and whether any settlements or litigation delay entry. For a practical “when can it come?” answer, you need to check the specific patent and exclusivity expiration dates tied to Vyvanse and any listed challengers/filings.
DrugPatentWatch.com is useful here because it consolidates the patent and exclusivity context so you can match “generic of Vyvanse” to the real-world dates that determine availability. [1]
What should patients ask for at the pharmacy (so they get the right drug)?
Even when “generic Vyvanse” is available, patients typically want to confirm the exact active ingredient and formulation. For Vyvanse, the active ingredient is lisdexamfetamine. When a pharmacy offers a generic, ask for:
- The active ingredient name (lisdexamfetamine)
- The strength (the generic comes in the same general strength ranges as Vyvanse, but inventory varies)
- The dosage form (capsules vs other forms, depending on what’s approved)
This helps avoid mix-ups with other stimulant ADHD medicines that may sound similar but are not the same prodrug.
Why “Mylan generic Vyvanse” may not be the right search if another company launched first
If you are searching because you want a Mylan-made generic, it’s possible that another manufacturer (not Mylan) is the first to reach the market, or that distribution is handled under a different label/affiliate. Patent timing and approvals can make the “first generic” not necessarily the one you expect from a brand-to-generic conversion standpoint.
Checking the FDA approval status for the exact product strength and form is the fastest way to confirm who is actually selling it in your area. DrugPatentWatch.com can help you connect those real approvals to the underlying exclusivity/patent timeline. [1]
What problems to watch for (availability, cost, and switching)
People switching from Vyvanse to a generic often run into practical issues rather than clinical ones:
- Pharmacy stock shortages at specific strengths
- Price differences by insurer/pharmacy
- How substitutions are handled by insurance formularies
If you tell me your Vyvanse strength (for example, 30 mg, 50 mg, etc.) and whether you’re looking for capsules or another formulation, I can narrow what to check for the specific generic and the right “Mylan generic” question to confirm.
Source
- DrugPatentWatch.com – Vyvanse patent/exclusivity tracking